SCHEMBL22093038

SCHEMBL22093038

NC(=O)c1ccc(C(F)(F)F)nc1Nc1ccccc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.60
HTT P42858 1/20 0.60
LMNA P02545 1/20 0.55
PIM1 P11309 2/20 0.47
PIM2 Q9P1W9 1/20 0.47
MAPK8 P45983 1/20 0.45
CDC7 O00311 1/20 0.44
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
PRKACA P17612 1/20 0.44
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
TAS2R14 Q9NYV8 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SYK P43405 3/20 0.41
JAK2 O60674 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CDK5 Q00535 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31145536 1.00 MAPT (0.60) MAPTHTTLMNAPIM1PIM2
SCHEMBL31145518 0.86 MAPK8 (0.44) MAPTHTTLMNAPIM1MAPK8
SCHEMBL22093011 0.86 MAPK8 (0.44) MAPTHTTLMNAPIM1MAPK8
SCHEMBL22093021 0.82 MAPK8 (0.51) LMNAPIM1MAPK8CDC7ROCK2
SCHEMBL24596390 0.76 LMNA (0.45) MAPTHTTLMNATAS2R14SMN1; SMN2
SCHEMBL26631681 0.76 TAS2R14 (0.49) LMNAMAPK8CDC7TAS2R14SYK
SCHEMBL29789888 0.74 TAS2R14 (0.52) MAPTLMNAPIM1PIM2TAS2R14
SCHEMBL24596386 0.74 TAS2R14 (0.52) MAPTLMNAPIM1PIM2TAS2R14
SCHEMBL26631653 0.73 LMNA (0.45) MAPTHTTLMNATAS2R14SMN1; SMN2
SCHEMBL29305777 0.71 DUSP26 (0.46) TAS2R14KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MAPT 1760/4885HTT 4088/4885LMNA 3298/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MAPT 1760/4885HTT 4088/4885LMNA 3298/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MAPT 1760/4885HTT 4088/4885LMNA 3298/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A MAPT 1760/4885HTT 4088/4885LMNA 3298/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A MAPT 1760/4885HTT 4088/4885LMNA 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.